Merck Introduces Mobius® MyWay Portfolio for Customized Single-Use Assemblies

• New portfolio provides shorter lead times for more rapid biomanufacturing
• Optimizes balance of delivery speed and customization

Darmstadt, Germany, March 21, 2017 — Merck, a leading science and technology company, today launched an industry first — the Mobius® MyWay portfolio, a program that allows more flexibility, better supply predictability and shorter lead times for more efficient and safer drug manufacture.

“We have the industry’s only comprehensive single-use solution, giving customers three different ways to create customizable assemblies,” said Andrew Bulpin, Head of Process Solutions Strategic Marketing & Innovation at the life science business sector of Merck. “This is critical to customers from contract manufacturing organizations to big pharma, whose biggest challenge is getting custom assemblies with fast, reliable lead times for quicker turnarounds and more rapid biomanufacturing.”

For commercial manufacturers, Merck’s Mobius® MyWay portfolio helps minimize schedule disruptions and delays. Pilot plants benefit from faster assembly design and delivery in order to adjust to new and evolving needs in real-time. Contract manufacturing organizations benefit from more reliable lead times allowing for better planning, which helps ensure on-time product delivery.

Merck’s portfolio offers a choice of off-the-shelf and configured-to-order assemblies, as well as fully customizable configurations. Assemblies available as part of the Mobius® MyWay portfolio are used for safe and effective fluid management across upstream and downstream processes, from routine buffer and media prep, to critical premium aseptic process and final drug manufacturing.

Assemblies are segmented into three categories, each offering a different level of configuration flexibility:

• Mobius® Stock offers on-demand solutions ready to ship in 24 hours.
• Mobius® Select offers an optimal balance of speed and configurability of custom assemblies from an optimized component library with an agile 6-week lead time.
• Mobius® Choice offers highly customized solutions from our expansive component library, shipped in standard lead times.

Among the assemblies included in the Mobius® MyWay portfolio are Mobius® MIX systems and bags up to 1,000 liters; holding and transport vessels up to 3,500 liters; Lynx® CDR sterile connectors and single-use final formulation, filtration and final fill assemblies.

メルクについて
Merck（メルク）はヘルスケア、ライフサイエンス、パフォーマンスマテリアルズの分野における世界有数のサイエンスとテクノロジー企業です。がんや多発性硬化症のためのバイオ医薬品を用いた治療法から、科学研究と生産に関する最先端システム、スマートフォンや液晶テレビ向けの液晶材料にいたるまで、約53,000人の従業員が人々の暮らしをより良くする技術の一層の進歩を目指しています。2017年は66カ国で153億ユーロの売上高を計上しました。

メルクは1668年に創業された世界で最も歴史の長い医薬・化学品会社で、 創業家が今でも、上場企業が率いるメルクグループの株式の過半数を所有しています。メルクの名称およびブランドのグローバルな権利は、メルクが保有しています。唯一の例外は米国とカナダで、両国ではEMDセローノ、ミリポアシグマ、EMDパフォーマンスマテリアルズとして事業を行っています。